Company intelligence / Profile preview

MD Stem Cells

Ownership: Private
Development stage: Other

Overview

MD Stem Cells provides stem cell treatments for ophthalmic and neurologic diseases using adult, bone marrow-derived stem cells. Their therapies are conducted exclusively in the United States under FDA-compliant protocols, with Institutional Review Board approval and NIH registration. The company reports statistically significant results in peer-reviewed publications, with hundreds of patients treated and many experiencing meaningful improvements.

Therapeutic areas: OphthalmologyNeurology
Modalities: Stem cell therapyCell therapy
Industry: Biotech

Drug pipeline

2 assets

autologous bone marrow-derived stem cells (MD Stem Cells)

Unknown

1 more asset in the full pipeline.

Request access →

Partnerships

The Healing Institute of Florida

Beyond the preview

Go deeper on MD Stem Cells.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MD Stem Cells.

Explore the full profile